Abstract:Iron is an essential trace nutrient for nearly all living organisms. The element readily donates or accepts electrons and is the key working component of many enzymes involved in oxidation and reduction reactions and of proteins that transport or store oxygen. Rapidly proliferating cancer cells require increased biosynthetic activity and therefore are highly dependent on their iron supply. In turn, the presence of cancer cells in the body elicits inflammatory responses which affect iron homeostasis, partly through the induction of the iron-regulatory hepatic hormone hepcidin. Increased hepcidin concentrations cause the endocytosis of the cellular iron exporter ferro-portin, leading to iron sequestration in macrophages, decreased iron absorption in the proximal duodenum, and the development of a characteristic anemia of cancer caused in part by restriction of the iron availability to developing erythro-cytes in the marrow. The two-way interaction between cancers and systemic iron homeostasis is the subject of this volume, which was inspired by recent advances in this area. Iron can be carcinogenic: in excessive amounts, iron is toxic to cells, probably by catalyzing the production of reactive oxygen species. Iron-induced tissue injury in the liver can initiate carcino-genesis, and hepatocarcinoma is a common complication of cirrhosis in the setting of iron overload disorders, especially hereditary hemochromatosis (Article 1). Cancer cells evolve clonally, favoring molecular adaptations that help make sufficient iron available for their rapid proliferation. In turn, iron-related molecular adaptations impact cancer prognosis and are potential targets for therapy. In some cases, the heightened dependence of cancer cells on iron can be therapeutically targeted through iron chelators (Article 2). In breast cancer, the supper-ssion of the cellular iron exporter ferroportin (Article 3) is a strong adverse prognostic marker and another potential therapeutic target. In myeloma, the over-expression on cancer cells of the transferrin receptor (TfR1) through which tumors take up transferrin-bound iron allows therapeutic targeting by antibodies (Article 4). Although human tumors evolve from their host's cells, they often display neoantigens or secrete factors that elicit an inflammatory response, contributing to the clinically important anemias associated with cancer (Articles 4–6). The pathogenesis of these ane-mias is mediated by inflammatory cytokines, in part through a direct suppressive effect on erythropoiesis and in part through the stimulation of the iron hormone hepcidin and the restriction of iron supply to erythropoiesis. The cytokine-mediated mechanisms of anemia of cancer are particularly prominent and best understood in myeloma (Article 4) and Hodgkin lymphoma (Article 5). …

Liver Cancer Cells Uptake Labile Iron via L-type Calcium Channel to Facilitate the Cancer Cell Proliferation

Upregulation of transferrin receptor-1 induces cholangiocarcinoma progression via induction of labile iron pool

Iron Regulates Cellular Proliferation by Enhancing the Expression of Glucose Transporter GLUT3 in the Liver

Probing Iron-Mediated Synergistic Change of Cl- and HClO in Liver Cancer Cells with a Dual-Color Fluorescence Reporter

Iron Metabolism, Ferroptosis, and Lncrna in Cancer: Knowns and Unknowns

Preface: iron and cancer.

Protein Alteration of HepG2.2.15 Cells Induced by Iron Overload.

Tumor Associated Macrophages Deliver Iron to Tumor Cells Via Lcn2.

Response to iron overload in cultured hepatocytes

Prolactin Drives Iron Release from Macrophages and Uptake in Mammary Cancer Cells through CD44

Growth Inhibition of a Novel Iron Chelator, DpdtC, Against Hepatoma Carcinoma Cell Lines Partly Attributed to Ferritinophagy-Mediated Lysosomal ROS Generation

Iron and cancer: recent insights

Iron promotes breast cancer cell migration via IL-6/JAK2/STAT3 signaling pathways in a paracrine or autocrine IL-6-rich inflammatory environment.

Iron Regulates the Warburg Effect and Ferroptosis in Colorectal Cancer

Iron Depletion Participates in the Suppression of Cell Proliferation Induced by Lipin1 Overexpression.

Transferrin-inspired iron delivery across the cell membrane using [(L2Fe)2(μ-O)] (L = chlorquinaldol) to harness anticancer activity of ferroptosis

Iron deprivation suppresses hepatocellular carcinoma growth in experimental studies.

Paradoxical Proliferative Potential of Iron (II) Sulphate on Cancer Cells after the 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2h-tetrazolium (MTS) Assay.

Study On The Role Of Iron In Migration Of Human Breast Cancer Cells

A Role of Functional T-type Ca2+ Channel in Hepatocellular Carcinoma Cell Proliferation.

Iron metabolism and its contribution to cancer (Review)